Linked Life Data

15908126

Source:http://linkedlifedata.com/resource/pubmed/id/15908126

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
2005-7-25
pubmed:abstractText
Fulvestrant, a new type of oestrogen receptor antagonist with no agonist effects, is now licensed in the EU and USA for the treatment of postmenopausal women with hormone-sensitive advanced breast cancer following progression on prior antioestrogen therapy. Approval was based on data from two phase III trials that demonstrated fulvestrant was at least as effective as the third-generation aromatase inhibitor (AI) anastrozole as a second-line treatment for advanced breast cancer. The third-generation AIs letrozole and exemestane also demonstrate efficacy after tamoxifen failure. To compare the performance of fulvestrant and contemporary endocrine treatments (anastrozole, letrozole and exemestane) in tamoxifen-resistant disease, we conducted a literature review using the PubMed database. These indirect comparisons suggest that fulvestrant offers similar efficacy and tolerability to other second-line treatments for postmenopausal women with advanced breast cancer. Findings from these comparisons support the use of fulvestrant as an additional second-line endocrine treatment option in this setting. New trials are assessing the efficacy of fulvestrant as a second-line treatment following AI failure. The integration of new agents such as fulvestrant into the endocrine sequence may extend the endocrine treatment window, before cytotoxic chemotherapy needs to be considered, and therefore improve patient quality of life.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
0305-7372
pubmed:author
pubmed:issnType
Print
pubmed:volume
31
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
274-82
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed:year
2005
pubmed:articleTitle
A comparison of fulvestrant and the third-generation aromatase inhibitors in the second-line treatment of postmenopausal women with advanced breast cancer.
pubmed:affiliation
Cookridge Hospital, Leeds, Yorkshire LS16 6QB, UK. david.dodwell@leedsth.nhs.uk
pubmed:publicationType
Journal Article, Review